您当前的位置:  主页 > 新闻中心 >
  • While single-cell genomic methods are feasible in some research settings, they won’t be useful in the clinic until improvements are made in reducing the cost and time of sequencing. Fortunately, the cost of DNA sequencing is falling precipitously as a direct result of industry competition and technological innovation. Sequencing has an extra benefit over microarrays in the potential for massive multiplexing of samples using barcoding strategies
  • 术毕冲洗术区,逐层缝合切口。
  • 婚后的第一次新年
  • 是因为他真的只是在敷衍你
  • Advances in whole genome amplification and next-generation sequencing methods have enabled genomic data analysis of single cells. Meanwhile, these techniques are now beginning to be utilized to detect genomic lesions in individual cancer cells. Previous approaches have been unable to resolve genomic differences in complex mixtures of cells, such as heterogeneous tumors, despite the significance of characterizing such tumors for cancer treatment. Sequencing of single cells(single-cell seq) is likely to improve several aspects of medicine, including the early detection of rare tumor cells, monitoring of circulating tumor cells (CTCs), measuring intratumor heterogeneity, and guiding chemotherapy. There are also lots of challenges and technical aspects of single-cell sequencing,and we also need to know how this information can be used to diagnose and treat cancer patients.The clinical value of single-cell genomic methods will be in monitoring CTCs, profiling rare cancer cells in clinical samples, and detecting rare clones that may be resistant to chemotherapy. These applications are likely to improve all the three major themes of oncology: detection, progression, and prediction of therapeutic efficacy.